

In April 2011, sanofi-aventis issued the press releases attached hereto as Exhibits 99.1 to 99.5 which are incorporated herein by reference.

Exhibit List

Exhibit No.	Description
Exhibit 99.1	Press release dated April 5, 2011: Data from Two Mipomersen Phase 3 Trials Presented at ACC
Exhibit 99.2	Press release dated April 7, 2011: Genzyme Presents New Data from Alemtuzumab Phase 2 MS Trial at 63rd Annual Meeting of the American Academy of Neurology
Exhibit 99.3	Press release dated April 8, 2011: Sanofi-Aventis Completes Acquisition of Genzyme Corporation
Exhibit 99.4	Press release dated April 12, 2011: Lixisenatide Significantly Reduces HbA1c without Increasing Hypoglycemia in Patients Uncontrolled on Sulfonylureas
Exhibit 99.5	Press release dated April 14, 2011: Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: April 20, 2011

SANOFI-AVENTIS

By /S/ John Felitti
Name: John Felitti
Title: Associate Vice President,

Corporate Law, Financial &

Securities Law

Exhibit Index

Exhibit No.	Description
Exhibit 99.1	Press release dated April 5, 2011: Data from Two Mipomersen Phase 3 Trials Presented at ACC
Exhibit 99.2	Press release dated April 7, 2011: Genzyme Presents New Data from Alemtuzumab Phase 2 MS Trial at 63rd Annual Meeting of the American Academy of Neurology
Exhibit 99.3	Press release dated April 8, 2011: Sanofi-Aventis Completes Acquisition of Genzyme Corporation
Exhibit 99.4	Press release dated April 12, 2011: Lixisenatide Significantly Reduces HbA1c without Increasing Hypoglycemia in Patients Uncontrolled on Sulfonylureas
Exhibit 99.5	Press release dated April 14, 2011: Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease